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Calling on Science:  
Making “Alternatives” the New Gold Standard1 
Melvin E. Andersen
the Hamner Institutes for Health Sciences, Research triangle Park, NC, USA 
Summary
All of life’s great journeys start with a goal in mind! The 2007 NAS report, Toxicity Testing in the 21st 
Century – A Vision and A Strategy, has proposed a clear goal. This report envisions a not-so-distant future 
where all routine toxicity testing for environmental agents will be conducted in human cells in vitro evaluat-
ing perturbations of cellular responses in a suite of toxicity pathway assays. Dose response modeling would 
utilize computational systems biology models of the circuitry underlying each toxicity pathway; in vitro to 
in vivo extrapolations would use pharmacokinetic models, ideally physiologically based pharmacokinetic 
models, to predict human blood and tissue concentrations under specific exposure conditions. Results from 
these toxicity pathway assays and associated dose response modeling tools rather than those from high 
dose studies in animals would represent the new gold standard for chemical risk assessment. This talk 
focuses on some of the scientific challenges required to make this vision a reality, including characteristics 
of assay design, prospects for mapping and modeling toxicity pathways, assay validation, and biokinetic 
modeling. All of these tools necessary for this transformation of toxicity testing to an in vitro platform are 
either available or in advanced development. Science must lead the transformation. The scientific com-
munity, animal alternatives groups, regulatory agencies, and funding organizations will also have to muster 
the resolve to work together to make this vision a reality.
Keywords: gold standard, toxicity pathways, in vitro biology, computational systems biology, toxicity testing 
transformation
1 Several of the ideas in the introductory portion of this paper reflect those from two previous contributions (Krewski et al., 
2009; Andersen and Krewski, 2009). The interested reader should also consult these two papers.
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1  Introduction
this year marks the 50th anniversary of the publication of The 
Principles of Humane Experimental Technique by William Rus-
sell and Rex Burch. their contribution focused attention on the 
3Rs – replacement, reduction, and refinement. In toxicity testing, 
the primary initiative with the 3Rs in the intervening decades 
has arguably focused on reduction of animal usage while holding 
firm the belief that results from animal studies provide a “Gold 
Standard” for making decisions about possible human health 
risks of compounds. The very wording, “alternatives”, has often 
been regarded by many in toxicology as those test methods that 
will reduce animal usage even though the result from the tests 
are not necessarily optimal for risk assessment decision-making. 
A second challenge in reduction of animal use through mecha-
nistically-based testing arises from the idea of validating “alter-
natives”. the process of validation with alternatives, in general, 
focuses on the ability of a test or a series of tests to give results 
consistent with those that would be obtained through testing in 
animals. In this context, all alternatives will fall short of the mark 
of complete concordance with in vivo outcomes. Are all efforts 
to reduce animal use significantly doomed to disaster as they are 
dashed against the “gold standard” barrier? 
the recommendations of a recent report (NRC, 2007) from 
the US National Academy of Sciences, Toxicity Testing in the 
21st Century: A Vision and A Strategy argues that it is time to 
redefine the toxicity testing paradigm, moving away from high 
dose studies in animals to in vitro assays assessing perturba-
tions of toxicity pathways by environmental agents. In essence, 
the report supports a sweeping redefinition of our “gold stand-
ard.” the author of this present paper was a member of the NAS 
toxicity testing committee. Since the publication of the NAS 
report in June 2007, several of the NAS committee members 
have presented aspects of the report at more than 40 venues in 
North America and europe. these presentations and the lively 
debate engendered on these occasions have sharpened ideas 
about the use of results from in vitro toxicity pathway assays in 
risk or safety assessments. the NAS report, although published 
in 2007, was essentially completed in fall 2006. Advances in 
several key technologies in the past three years – especially 
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assessing human health effects of environmental chemicals, 
including knowledge of modes of action, and (4) minimizing 
use of animals in testing. the consideration of how these crite-
ria should guide a modern approach to toxicity testing led the 
committee to propose a new framework for toxicity testing that 
would entail a major overhaul of current practice. 
Toxicity testing and targeted in life studies
the NAS committee vision consisted of several key technology 
areas (Fig. 1). While also including in silico methods for assess-
ing structure activity relationships and population assessments, 
the transformative parts of their new toxicity testing paradigm 
was the types of toxicity testing and the manner in which results 
from these tests could be organized to support human health 
risk assessment. This vision centers on defining dose-response 
relationships for toxicity pathway perturbations that would be 
expected to lead to adverse health outcomes if the perturbations 
were maintained in vivo at a sufficient level of intensity and for 
a sufficient duration of exposure. The key component of the vi-
sion is assaying perturbations of toxicity pathways, which are 
simply normal biological signalling pathways that may be per-
turbed by chemical exposures. toxicity pathway testing would 
require a suite of in vitro tests that could identify the range of 
significant perturbations of human pathways that might occur as 
stem cell biology, computational systems biology, and pathway 
mapping and modeling – appear likely to be key catalysts for 
moving the vision forward. Finally, the transformation from 
current, traditional approaches to new in vitro methods based 
on human biology will not come easily. Who will step up to as-
sist in the transformation to a new approach to testing and risk 
assessment? Several initiatives within the United States, both 
in federal government research organizations and in the private 
sector, look likely to accelerate implementation. these topics – 
(1) the recommendations from the NAS report, (2) the manner 
in which the in vitro toxicity pathway data can be organized for 
risk/safety assessments, (3) the call to the alternatives commu-
nity to embrace 21st century computational and bioinformatics 
methodologies in designing and interpreting in vitro results, and 
(4) the institutional opportunities to accelerate implementation 
of the NAS vision – are discussed in turn in this current paper.
2  Toxicity Testing in the 21st Century:  
a Vision and a Strategy
the US environmental Protection Agency and the US National 
Institute of environmental Health Sciences asked the US Na-
tional Research Council (NRC) to provide guidance on new 
directions in toxicity testing, incorporating emerging technolo-
gies such as genomics and computational systems biology into 
a new vision for toxicity testing. In 2004, the NRC convened 
a 22 person committee for this purpose (tab. 1). the commit-
tee produced two reports. the committee’s interim report (NRC, 
2006) provided an overview of testing methods and approaches 
that could incrementally improve traditional toxicity testing. 
this report noted that health protection agencies and the public 
had experienced increasing frustration with the failure of cur-
rent approaches to toxicity testing to provide timely, relevant 
information to support informed regulation of environmental 
agents. these toxicity testing strategies relied primarily on the 
observation of adverse health responses in laboratory animals 
treated with high doses of these agents. estimating risks to hu-
man populations based on high dose animal studies require diffi-
cult extrapolations, first from high doses to environmental levels 
that are usually orders-of-magnitude lower than those used in 
the animal studies, and then from animals to humans. these tra-
ditional toxicity testing approaches and methods for their inter-
pretation date back some 30 to 60 years, and were developed at 
a time when knowledge of biology – and of the manner in which 
chemical exposures perturbed biological processes – was primi-
tive. While there have been steady, incremental improvements in 
toxicity testing over the years, there has been no comprehensive 
evaluation of the manner in which advances in cellular and mo-
lecular biology might improve toxicity testing practices. 
The final report of the toxicity testing committee (NRC, 2007) 
outlined design criteria that needed to be considered in any 
revisions of practices for toxicity testing. In choosing among 
various toxicity testing options, four criteria are important: (1) 
achieving broad coverage of chemicals, chemical mixtures, out-
comes, and life stages, (2) reducing the cost and time required 
for toxicity testing, (3) developing a better scientific basis for 
Tab. 1: The Roster of the NRC Toxicity Testing Committee
Daniel Krewski (Chair), University of Ottawa, Ottawa, ON
Daniel Acosta, Jr., University of Cincinnati, Cincinnati, OH
Melvin Andersen, The Hamner Institutes for Health Sciences, 
Research Triangle Park, NC 
Henry Anderson, Wisconsin Division of Public Health, Madison, WI 
John Bailar III, University of Chicago, Chicago, IL 
Kim Boekelheide, Brown University, Providence, RI 
Robert Brent, Thomas Jefferson University, Wilmington, DE 
Gail Charnley, HealthRisk Strategies, Washington, DC 
Vivian Cheung, University of Pennsylvania, Philadelphia, PA 
Sidney Green, Howard University, Washington, DC 
Karl Kelsey, Harvard University, Boston, MA 
Nancy Kerkvliet, Oregon State University, Corvallis, OR 
Abby Li, Exponent, Inc., San Francisco, CA 
Lawrence McCray, Massachusetts Institute of Technology,  
Cambridge MA 
Otto Meyer, Danish Institute for Food and Veterinary Research, 
Søborg, Denmark 
D. Reid Patterson, Reid Patterson Consulting, Inc., Grayslake, IL 
William Pennie, Pfizer, Inc., Groton, CT 
Robert Scala, Exxon Biomedical Sciences (Ret.), Tucson, AZ 
Gina Solomon, Natural Resources Defense Council,  
San Francisco, CA 
Martin Stephens, The Humane Society of the United States, 
Washington, DC 
James Yager, Jr., Johns Hopkins University, Baltimore, MD 
Lauren Zeise, California Environmental Protection Agency,  
Oakland, CA
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with human cells would markedly reduce the need for whole 
animal testing, and provide much stronger, mechanistically-
based tools for human health safety assessment. It was recog-
nized that the conversion to an in vitro basis had challenges and 
the committee also suggested that targeted in vitro testing was 
also likely to continue for some time where such studies could 
provide information about metabolism, possible metabolite tox-
icity, toxicity pathways, etc. Metabolism has been recognized as 
a particular challenge for developing in vitro testing alternatives 
(Coecke et al., 2006).
Dose-response and extrapolation modeling 
How will results from a comprehensive suite of toxicity path-
ways inform quantitative risk/safety assessments for environ-
mental agents? In this new toxicity testing strategy, in vitro 
concentration response curve would cover multiple orders of 
magnitude (Inglese et al., 2006, 2007) and evaluate responses 
in cells/tissues from humans, the species of primary interest. 
The broad range of concentrations permit the definition of dose 
ranges resulting, or not resulting, in significant alterations of 
normal biological function. While low dose and interspecies ex-
trapolations are not as problematic, new challenges arise in un-
derstanding the mechanistic bases for dose-response behaviors 
of the toxicity pathway assays, in calibrating expected blood/
tissue concentrations in humans against the vitro concentrations 
used in the toxicity pathway assays, and in understanding the 
linkages of early perturbations to adverse responses expected in 
exposed people. The report identified key technologies that will 
assist dose response and in vitro-in vivo extrapolations, includ-
ing (1) empirical dose-response models based on results from 
the in vitro, mechanistically based toxicity pathway assays, (2) 
mechanistic dose-response models based on knowledge of tox-
icity pathway circuitry and dynamics of pathway function, and 
a result of chemical exposure (Fig. 2). Biologic responses are 
viewed as results of an intersection of exposure and biologic 
function. the intersection results in perturbation of biologic 
pathways. the circuitry affected by the chemical is expected to 
determine shapes of dose response relationships for these per-
turbations. Ideally, these assays would be conducted in human 
cells, cell lines or in engineered human tissues. the committee 
believed that the use of a comprehensive array of in vitro tests 
Fig. 1: Number of animals used for experiments in Germany (until 2000) and for animal experiments and other scientific 
purposes (since 2000).
tg = transgenic, WT = wild type. (Courtesy of Prof. Dr. Rainer Nobiling)
Fig. 1: Components of the vision for Toxicity Testing in the 
21st Century (NRC, 2007). 
The key elements in this proposal are related to Toxicity Testing, 
which includes the types of in vitro tests and short term  
in vivo tests to evaluate perturbations on toxicity pathways, and 
Dose-Response and Extrapolation Modeling, which provides  
the requisite tools for interpreting toxicity testing results for 
assessing human health risk assessment. Reproduced from  
the NRC report (NRC, 2007) with permission.
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activation of the pathway on through degrees of perturbation 
that would be considered sufficiently large to be associated with 
likely toxicity if maintained over a period of time in an intact or-
ganism. For most, if not all assays, concentrations are expected 
to range from sub-threshold through those causing initial path-
way activation, on to regions of adaptation, and finally to those 
causing adverse cellular consequences. to cover these various 
degrees of response, each assay would likely provide different 
levels of biological readout as a function of concentration and 
duration of treatment.
Each pathway assay is expected to have specific dose re-
sponse characteristics depending on the organization of the cir-
cuitry that determines the action of compounds on the toxicity 
pathway. the dose response behaviors should arise from the 
underlying biology of the circuitry. these core signaling proc-
esses include the initial signal recognition and then the larger 
scale network through which the initial perturbation progresses 
to generate toxicity in the test system. Computational systems 
biology (Alon, 2006, 2007) provides the tools for describing 
these circuits and the differential behavior of the circuits with 
increasing degrees of perturbation. 
the process of validating toxicity pathway assays would be to 
study its behavior for positive control compounds and to extract 
the network structure and network dynamics that determine 
dose response. the sequential passage from sub-threshold, to 
adaptive, to toxic conditions represents dose-dependent transi-
tions in modes of action in an in vitro system. Dose-dependent 
(3) physiologically based pharmacokinetic (PBPK) models to 
equate tissue-media concentrations with tissue dose in exposed 
people. two recent perspectives on the NAS report provide 
good overviews of the report and directions for implementation 
(Krewski et al., 2009; Andersen and Krewski, 2009). 
3  The new gold standard in practice
Over the past three years, there has been continuing discussions 
about the NAS report with diverse stakeholder audiences. Dur-
ing these discussions, many questions were directed at the man-
ner in which the pieces of the new test paradigm would integrate 
together to provide quantitative approaches for risk or safety 
assessment. the NAS report did outline two hypothetical cases 
of “assessments” that might arise from a battery of in vitro test 
using examples of a reactive gas and of a compound with estro-
genic activity. these examples were cursorily developed, but 
indicated how various parts of the testing and analysis would 
likely contribute to health assessments. It is possible today to 
provide a more complete picture of how these pieces might be 
integrated (Fig. 3).
the core component of the testing will be the suite of toxicity 
pathway assays (Fig. 3; section i). these assays would be devel-
oped for human cells, human cells in culture, or human three-di-
mensional tissue surrogates. the toxicity test assays themselves 
need to be capable of evaluating the progression from initial 
Fig. 3: Representation of the application of in vitro toxicity testing results for risk assessment. 
Four components will contribute. (1) The suite of assays to provide broad coverage of possible targets and mechanisms of toxicity.  
(2) The mapping and modeling tools to validate pathway architecture and provide dose-response models for risk assessment.  
(3) The flexibility in assay output to evaluate networks that incrementally control target interactions, adaptive stress responses and  
overt toxicity. Lastly, (4) the use of PBPK and biokinetic tools to relate in vitro concentrations with in vivo exposures.
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transitions in in vivo toxicology studies are well known (Slikker 
et al., 2004a, 2004b). this type of response cascade has been de-
scribed in vitro by xiao et al. (2003) and by Nel et al. (2006) in 
work on hierarchical oxidative stress. Feedback process control 
and dose response have also been examined more theoretically 
for anti-stress gene regulatory networks (Zhang and Andersen, 
2007). Alon (2007) has provided a good overview of network 
motifs in signaling pathways and in what were termed “devel-
opmental” networks. In practice, toxicity pathway characteri-
zation would optimally include standard operating procedures 
(SOPs) for preparing cells, conducting specific assays, generat-
ing read-outs, and the detailed process by which the pathway 
structure, circuit, and dynamics had been evaluated to support 
dose-response modeling. the detailed pathway characterization 
(essentially the process of validation of the pathway behavior) 
would be the mainstay of dose response analyses. For the safety 
assessment, primary attention would focus on pathways affected 
at the lowest concentration (Fig. 3; sections ii and iii). 
How do we relate concentrations affecting cells in vitro with 
exposures in human populations likely to cause similar respons-
es in an intact individual? Human biomonitoring for chemicals 
in blood and excreta is becoming more widespread. In some 
instances, concentrations of exogenous compounds in humans 
may be available. Comparisons could be made between those 
concentrations seen in exposed populations and those affect-
ing cells in the toxicity pathways assays in order to estimate a 
“margin of safety” or “margin of exposure.” This comparison 
is unlikely to be possible with very many compounds. A more 
general methodology would be development of biokinetic mod-
els (DeJongh et al., 1999) to determine the human exposure sit-
uations expected to give cell and tissue concentrations similar to 
those affecting the human cells in the in vitro pathway assay test 
(Fig. 3; iv). these approaches are extensions of the physiologi-
cally based pharmacokinetic types of models that have been of 
interest both with toxic substances and pharmaceuticals (Reddy 
et al., 2005; Bouvier d’Yvoire et al., 2007). A coordinated effort 
is required to develop a larger suite of PBPK models and to en-
hance efforts in reverse dosimetry, i.e., estimating the exposure 
levels in a human population that produce specific blood/tissue 
concentrations (Clewell et al., 2008). Current efforts to improve 
dosimetry methods are also advancing in vitro-in vivo extrapo-
lation tools (Gulden and Seibert, 2003; Heringa et al., 2004).
the risk assessment process would entail running the suite of 
assays for a compound to see the pattern of activation of path-
ways and the concentrations at which effects were noted in vari-
ous pathway assays. the most sensitive hits from the suite of 
assays would then be organized to support both dose response 
modeling and in vitro-in vivo extrapolation. the pattern of ac-
tivity across the suite of assays could also provide signatures to 
indicate the types of toxic endpoints that might be observed in 
vivo (Dix et al., 2007). For example, specific signatures might 
indicate a high likelihood of reproductive toxicity or of hepatic 
toxicity in a qualitative manner. 
Risk assessments completed based on results from these tox-
icity pathway assays are likely to be quite different from those 
arising from current approaches. today, we see effects in ani-
mals, usually at fairly high doses, and estimate the likely inci-
dence of response at lower doses in exposed populations. For 
cancer, we might try to estimate the expected concentration 
estimated to give a 1/1,000,000 level of population risk. this 
process has two less than desirable outcomes – first, labeling 
compounds based on high dose hazard studies and (2) provid-
ing a false sense of precision regarding our ability to extrap-
olate across doses and species. For instance, if Compound A 
causes cancer, at a maximally tolerated dose, it becomes labeled 
as carcinogen regardless of considerations of exposure levels. 
Secondly, the public is led to believe that the estimates of the 
low dose extrapolations are scientifically valid without any ap-
preciation of the uncertainties about these estimates. In contrast, 
the assessments based on the in vitro toxicity pathway assays 
would be more directed at safety assessment, estimating regions 
of exposure where no appreciable perturbations are expected in 
human cells or human tissues in culture. 
4  Calling on 21st century science 
the NAS committee discussed a variety of key technology 
areas for toxicity testing in the 21st century. While the broad 
suite of new tools are likely to influence many areas of toxi-
cology research and to greatly improve understanding of cell 
signaling pathways, it is important to ask more narrowly how 
specific technologies and advances will contribute to the four 
components noted in Fig. 3. the three areas most likely to ben-
efit immediately are in assay design, using stem cell technology, 
pathway mapping and modeling, and computational systems bi-
ology for assessing expected dose response behaviors.
Assay design
A frequently voiced concern after publication of the report was 
the difficulty in obtaining and working with primary human cells 
and the caveats associated with use of human cell lines. the past 
few years have provided optimism in the ability to obtain tissue-
specific human and rodent stem cells from which more mature 
cell types can be generated (Alonso and Fuchs, 2003). the stem 
cells can be stored and grown as needed for assays and will 
likely become available for a wider and wider suite of tissues 
(Reya and Clever, 2005; Gaudio et al., 2009). Embryonic and 
fetal amniotic fluid stem cells can be used and differentiated 
through frequently tedious, multi-step processes to multiple cell 
types (DeCoppi et al., 2007). With tissue-specific stem cells, the 
route to mature cells is shorter and requires less manipulation 
(Wang et al., 2009). 
In addition to availability of tissue specific stem cells, other 
advances bringing biomedical and small-scale manufacturing 
processes offer opportunities to utilize human 3-dimensional 
tissue in higher throughput contexts. For instance, Khetani and 
Bhatia (2008) discuss the application of semiconductor manu-
facturing microtechnology for fabrication of microscale tissues. 
A miniaturized, multiwall culture system for human liver cells 
with optimized microscale architecture maintained phenotypic 
functions or several weeks. these organotypic cultures could be 
useful in insuring better correspondence between in vitro tests 
and expected behaviors in vivo. 
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signaling network is particularly well studied. Amit and col-
leagues (2007) used a suite of experimental and bioinformatic 
tools to determine the forward signaling and feedback proc-
esses controlling the EGF network. The network was dissected 
by transcriptional profiling coupled with reverse phase protein 
lysate assays that assessed phosphorylation states of proteins 
within the EGF pathway. The analysis provided the structure of 
the logic of the circuitry for the early, immediate and later stage 
portions of the network. 
Computational systems biology 
It appears likely that a major contribution of 21st century sci-
ence will be the application of an array of technologies to elu-
cidation, mapping and modeling the behavior of the test sys-
tems for assessing toxicity pathway dynamics. the tools would 
include mRNA, transcription factor and phospho-protein time 
course profiling, coupled with bioinformatic technologies to 
extract network structure. the outcome would provide dynam-
ics of the signaling networks and the dose-and time depend-
ence of expected consequences of perturbations by test com-
pounds, including positive controls for each of the pathways. 
Dynamic behavior of signaling networks have been described 
quantitatively using computational systems approaches focus-
ing on models of transcriptional control (Alon, 2007; Aldridge 
et al., 2006). theoretical descriptions of networks leading to 
better understanding of modular design elements in biologi-
cal circuits have refined our vocabulary – concepts of ultrasen-
sitivity, bistability, network gain, feedback and feed forward 
motifs, noise, stochasticity, and sequential levels of early, 
mid-term and late gene expression – to allow discussion of net-
work behaviors with some commonality of terminology. these 
concepts are more extensively elaborated in a course text on 
“Computational Systems Biology and Dose Response” avail-
able at the Hamner Institutes web-site (http://www.thehamner.
org/education-and-training/drm_workshop.html).
5  Creating the transformational mindset
In a Figure (5-1) in Chapter 5, the NAS report discussed a 
strategy for implementation, including ballpark estimates of 
the time (1 to 2 decades) and costs ($ 1-2 billion) for transition-
ing from current animal intensive toxicity testing to a toxicity 
pathway based approach. the report stressed the need for an 
organization to have the lead responsibility for overseeing the 
technology development to support the transition – a role that 
could eventually be played by an appropriate laboratory within 
the US National Institutes of Health. the overall timeline was 
shown in the report in a linear fashion leading to a transition to 
new approaches after completion of technology development 
for assays and achieving some confidence that the suite of as-
says would provide adequate coverage of possible pathway 
perturbations. In the current global economic climate and with 
a variety of competing interests for biomedical research, is it 
reasonable to expect federal agencies or the private sector to 
support such a long-term, expensive initiative? 
A major emphasis is required to produce appropriate assays 
with the right level of detail and an ability to provide appropri-
ate read-outs across different responses levels. For risk/safety 
assessments with a single compound, rapid, in vitro testing for 
the suite of pathways is essential. High throughput and high da-
ta content methods were emphasized in the NAS report. In this 
usage, high throughput assays allow evaluation of hundreds or 
thousands of compounds across multi-point dose response in a 
period of just a few days. Some assays such as the organotypic 
liver assay above may not be amenable to high throughput. 
For toxicity testing, it is useful to distinguish the need for high 
throughput methods for testing large numbers of compounds 
from efficient in vitro tests that can be done over the course of 
days but may not be easily scalable to the ultra-high through-
put. For evaluating the chemical space active for a particular 
pathway, high throughput permits evaluation pathway pertur-
bations for large compound libraries, leading to better in silico 
modeling of structure activity relationships. 
Mapping and modeling toxicity pathways 
Assay outputs can be diverse as clearly evident from the US 
ePA toxCast group of assays (Dix et al., 2007). Nonetheless, 
the area where the diverse array of new technologies has the 
greatest possible for contribution is in mapping and modeling 
the underlying signaling networks for specific toxicity path-
ways. the vast majority of perturbations are associated with 
networks that affect transcriptional control. Such a conclusion 
is obvious for so-called receptor-mediated toxicants, such as 
dioxin and the aryl hydrocarbon receptor, but is equally valid 
for stress response pathways. Antioxidant response signaling 
starts with oxidants reacting with cellular sensors – primarily 
Keap1. The modification of Keap1 leads to its dissociation 
from a complex with Nrf2, allowing Nrf2 and other partner-
ing proteins to form a promotional complex altering expres-
sion of genes controlling cellular anti-oxidants (Motohashi and 
Yamamoto, 2004).
As toxicity pathway circuitry becomes better understood over 
time, it will be possible to create computational systems biolo-
gy models for expected dose-response relationships for each of 
the assays used for toxicity testing following similar principles. 
Over the past decade, tools for mapping and modeling have 
blossomed. In a recent paper, Bromberg et al. (2008) described 
the network by which cannabinoid receptor (CB1R) controls 
neurite outgrowth. Activation of several hundred transcription 
factors within the nucleus after cell stimulation was measured 
to understand the logic of the signaling network. Bioinformatic 
methodologies connected CB1R to 23 activated transcription 
factors. experiments with pharmacological inhibitors of kinas-
es revealed a network organization of partial “OR” gates regu-
lating kinases stacked above AND gates that control transcrip-
tion factors. As in most instances of current research in systems 
pharmacology and network modeling, the goal of these stud-
ies was not dose-response as would be a primary interest for 
toxicity pathway analyses. this example provided a glimpse 
of the structure of the network without attempting a quantita-
tive computational model. The epidermal growth factor (EGF) 
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Some aspects of the NAS vision are embedded in other pro-
grams. three federal US agencies with responsibilities for 
health-related research – the environmental Protection Agency 
(ePA), the National Institute of environmental Health Scienc-
es’ National toxicology Program (NtP), and the National In-
stitutes of Health Chemical Genomics Center (NCGC) – have a 
memorandum of understanding to conduct research necessary 
to advance the NRC committee vision for the future of tox-
icity testing. Collaboration among these organizations in the 
US will be essential in establishing a national commitment to 
develop the scientific foundation of the vision. This collabora-
tion (Collins et al., 2008) focuses on research (1) to develop 
high throughput test methods, (2) to identify toxicity pathways, 
(3) to pursue targeted testing in short-term in vitro tests, and 
(4) to develop dose-response and extrapolation models. New 
approaches for in vitro toxicity testing and toxicity profiling 
are key parts of several federal programs in the US (Dix et 
al., 2007; National toxicology Program, 2004). the US ePA 
toxCast program (Dix et al., 2007) is using a variety of high 
throughput tests and computational methods to enhance priori-
tization of compounds for targeted testing in animals. A pro-
fessed goal of the new interagency collaboration is predicting 
high dose results in animals. Prioritization and predicting high 
dose results are not part of the NAS vision. Nonetheless, the 
tools and approaches being developed in this collaboration will 
be important for achieving the long-term vision for transform-
ing toxicity testing. Other tools will mature from efforts that 
are today primarily focused on animal alternatives (e.g., Spiel-
mann et al., 2000).
In the past year, the Humane Society of the United States 
(HSUS) and its affiliates, the Humane Society Legislative Fund 
(HSlF) and Humane Society International (HIS) have taken 
steps to enlist partners to a stakeholder consortium – the Hu-
man toxicology Project Consortium. the goal of this group is 
to facilitate the global shift to a cell response pathway para-
digm for chemical safety assessments. this shift, in the words 
of the consortium, holds great promise for more rapid predic-
tions of human health outcomes while superseding traditional 
animal testing for environmental agents and pharmaceuticals. 
the goals of this consortium is to (1) promote dialogue, infor-
mation sharing and establishment of a research and develop-
ment roadmap, (2) lobby for, coordinate and provide resources 
to support transatlantic efforts necessary to fulfill NAS vision, 
(3) engage in collaborative outreach to legislative, regulatory, 
corporate, academic and public interest audiences, and (4) to 
urgently develop a targeted research program to jump-start the 
transformation.
this targeted research plan, focusing on proof of concept ef-
forts, would first focus on prototype compounds and provide 
examples of the application of results from toxicity pathway as-
says for risk/safety assessments sequentially rather than waiting 
10 to 20 years to bring a totally new risk assessment paradigm 
on line. the proposed research over a 5 to 10 year period would 
provide examples with ten to fifteen pathway assays and gener-
ate opportunities for diverse stakeholders to gain experience in 
collecting and using these results for safety assessments. the 
outline of steps for this more targeted research program includes 
several components.
– Select about 10 prototypes compounds/pathway. these com-
pounds would be chosen based on the breadth of information 
about animal toxicity and of the expected toxicity pathway 
targets, serving as a test bed for examining relationships be-
tween in vitro toxicity test assays and historical information 
regarding in vivo results.
– Design appropriate cell-based toxicity assays. For these pro-
totype compounds, test assay systems would focus on both 
rodent and a human assay, preferentially using stem cells or 
mature cells derived from these stem cells. With one or more 
of the prototypes, 3-dimensional tissue systems could be used 
for the assays.
– Develop the next generation quantitative risk assessment 
tools. these assays would be subjected to mapping and mod-
eling analysis to uncover pathway circuitry, the dynamics of 
pathway responses to positive controls, and the dose response 
behaviors expected from different levels of perturbation.
– examine relationships between perturbations and toxicity 
for prototypes. the assay design would require consideration 
of cascades that contain initial target activation, adaptive re-
sponses, and adverse responses with prolonged levels of per-
turbation.
– Integrate results from studies to provide representative health 
risk/safety assessments. the outcome of each of the proto-
types would be risk/safety assessments that would be com-
pared to more conventional approaches from animal toxicity 
data sets. 
– Within the first 3-5 years expand from the first 10-prototypes 
to a larger suite of pathways/compounds. this transition 
should also allow some mid-course correction in the strat-
egy, stemming from a continuing evaluation of successes and 
challenges in applying the new science in assisting human 
health safety assessment.
– With success in getting the program jump-started through the 
consortium, other partners, including toxicity testing organi-
zations, regulatory agencies, and federal research organiza-
tions, could be enlisted as partners in moving forward with 
the transformation. 
Regardless of which organization seizes leadership for the ef-
forts to create the technology base for shifting to a new “Gold 
Standard,” the central question is whether such an initiative is a 
good public health investment. From the point-of-view of spar-
ing animal use and a more humane infrastructure for testing the 
answer has to be yes. Is it also likely to be a good investment 
in terms of its likely scientific value? The answer here is also 
a resounding yes! Our primary investment in toxicity testing 
today is simply box-checking, becoming a bit more mechanis-
tically oriented for high value chemicals that show responses 
in animal toxicity tests. the in vitro, human biology approach, 
elaborated here and arising from the NAS vision, has a much 
reduced emphasis on rote testing and much increased emphasis 
on generating detailed understanding of the signaling pathways 
affected by chemicals and how perturbations/modulations in 
these pathways affect biological outcome. these tools and ap-
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proaches will be just as valuable in drug safety/drug develop-
ment, in evaluation of safety of food and consumer products, 
and in ecotoxicology (Watanabe et al., in press). In addition to 
the broader applicability for human health outcomes for modu-
lation of these pathways (Fig. 4), the organization of informa-
tion on pathway structure and function is a natural post-genome 
program that could provide a better understanding of health, dis-
ease and susceptibility within the human population – a much 
preferred investment compared to today’s approach of in vivo 
testing and the cataloging of testing results.
6  Conclusions
toxicity testing and much of the discipline of toxicology have 
reached a tipping point. Old practices focusing primarily on high 
dose studies to evaluate end-organ toxicity in animals are giving 
way to modern practices that assess how chemicals are likely to 
affect human biology and the concentrations under which these 
effects might be expected in exposed humans. this change will 
not occur easily. even though the current toxicity testing is far 
from optimal, it is difficult to move away from entrenched tra-
ditional practices to a new footing. Change of this magnitude 
is discomfiting for most everyone. There are, of course, serious 
challenges to consider in such a transformation. they should 
not be dismissed or diminished. Chemical toxicity may relate 
to metabolism. How will the in vitro tests adequately assess 
metabolites with new compounds undergoing in vitro screen-
ing? Which of the observed perturbations will be considered 
appropriate for the safety assessment – will it be target activa-
tion, adaptive responses, or only some clear definition of overt 
toxicity in the cells? Will it be possible to describe circuitry for 
most toxicity pathways in enough detail to be confident in ex-
pected dose response behaviors? Finally, where will we find the 
scientists and regulators with the training and background to be 
comfortable with new practices? These issues are all important, 
legitimate questions that need to be considered. Yet, they should 
not divert us from the goal – to move toward a redefinition of 
the toxicity testing gold standard that focuses on human biology 
and perturbations of human toxicity pathways in vitro. We must 
bear in mind all the challenges, but push relentlessly toward the 
goal of a modern approach to human safety assessment.
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